newsfilter
← Earnings
Earnings Releases·

SIGA Technologies — Three and Nine Months Ended September 30, 2026 Earnings Summary

  • Total revenues declined 50% year-over-year to $1.3 million for the three months ended September 30, 2026, and fell 46% to $48.6 million for the nine-month period, driven by the fulfillment of the final $26 million IV TPOXX order under the U.S. 19C contract.
  • While the nine-month operating income dropped 94% to $2.1 million and net income fell 79% to $6.1 million, the company improved its quarterly operating loss to $6.5 million from $10.2 million in the prior year period.
  • The company secured a new $15 million Canadian procurement contract in October 2026 for oral TPOXX, featuring $9 million in firm commitments over the first three years, while cash and cash equivalents decreased to $116.4 million.
  • Strategic updates include the retirement of Executive Vice President Dennis Hrubry effective November 9, 2026, and ongoing efforts to diversify international government customers and secure a new U.S. Government procurement contract.
Company
SIGA TECHNOLOGIES INC
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic